Related Experiment Video

Updated: Jun 11, 2025

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K

Linking FOXM1 and PD-L1 to CDK4/6-MEK targeted therapy resistance in malignant peripheral nerve sheath tumors

Joshua J Lingo1,2, Ellen Voigt1,2,3, Dawn E Quelle1,2,3,4,5

  • 1Cancer Biology Graduate Program, University of Iowa, Iowa City, IA 52242, USA.

Oncotarget
|September 30, 2024
PubMed

Insights

Targeting CDK4/6, MEK, and PD-L1 shows promise for malignant peripheral nerve sheath tumors (MPNSTs). Further research into FOXM1 may overcome drug resistance and enhance immune responses against MPNSTs.

Area of Science:

  • Oncology
  • Cancer Immunology
  • Molecular Biology

Background:

  • Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas lacking effective treatments.
  • MPNSTs are driven by Ras hyperactivation, NF1 loss, and MEK/CDK4/6 pathway activation.

Purpose of the Study:

  • To investigate the efficacy of combined CDK4/6, MEK, and PD-L1 inhibition in MPNSTs.
  • To explore mechanisms of drug resistance and immune modulation in MPNSTs treated with targeted therapies.

Main Methods:

  • Utilized preclinical mouse models of MPNSTs.
  • Administered combination therapies targeting CDK4/6, MEK, and PD-L1.
  • Analyzed tumor immune microenvironment changes, including plasma cell accumulation.

Main Results:

  • Dual CDK4/6-MEK inhibition showed efficacy, enhanced by PD-L1 targeting.
  • Triple combination therapy led to MPNST regression and improved survival but eventual resistance.
  • CDK4/6-MEK inhibition induced unique immune activation with intratumoral plasma cells.

Conclusions:

  • PD-L1 and FOXM1 are linked and may mediate resistance to CDK4/6-MEK therapies.
  • FOXM1 may suppress anti-tumor immunity, hindering immunotherapy effectiveness.
  • Targeting the CDK4/6, MEK, PD-L1, and FOXM1 network offers potential future MPNST treatment strategies.
Keywords:
CDK4/6-MEK targetingFOXM1MPNSTPD-L1therapy resistance

More Related Videos

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

1.9K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K